Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
This review aims to explore the effects of GLP-1R signaling on various immune cells and evaluate the therapeutic potential of GLP-1RAs in autoimmune and autoinflammatory diseases, including psoriasis, inflammatory bowel diseases, rheumatoid arthritis, asthma, multiple sclerosis, Sjgrens syndrome, and systemic lupus erythematosus
This includes individuals with: Diagnosed MASLD or MASH, where GLP-1 therapy may offer therapeutic benefits but requires monitoring Chronic viral hepatitis (hepatitis B or C), particularly if transaminases are elevated Autoimmune hepatitis or other inflammatory liver conditions Cirrhosis or advanced fibrosis, where specialist consultation may be appropriate despite generally not requiring dose adjustment History of drug-induced liver injury from other agents For these patients, baseline comprehensive liver assessmentincluding liver enzymes, synthetic function tests (albumin, INR), and potentially imaging or non-invasive fibrosis markers (such as FIB-4 or ELF)helps establish a reference point for monitoring treatment effects
Improving Mitochondrial Function: One lesser-known aspect of GLP-1's impact is its ability to improve mitochondrial function
That's the objective transparency picture
Other oral medications : Foundayo causes a delay in gastric emptying, so it has the potential to impact the absorption of medications
Stomach problems, sometimes severe, have been reported in people who use Zepbound
US$ 24.45
US$ 29.31
US$ 25.64
